Hear From the Therapeutics Team

HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.

HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.

Technology

HTG Therapeutics leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.

Learn More

Drug Discovery Process

 

By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.

Learn More

 

Drug Discovery Pipeline

HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.

Learn More

HTG Therapeutics News & Events

2022 ASCO Annual Meeting

June 3-7 | Join us at booth 3135 in Chicago at the 2022 ASCO Annual Meeting and Expo.

Posted on:

Keep Reading

ESMO CONGRESS 2022

SEPTEMBER 9-13, 2022 | Join us at the European Society for Medical Oncology Congress in Paris, France

Posted on:

Keep Reading

The Festival of Genomics & Biodata 2023

January 25-26 | Come and see us in London at the 2023 Festival of Genomics

Posted on:

Keep Reading

HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference

TUCSON, Ariz. , May 17, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C….

Keep Reading

HTG Molecular Diagnostics Reports First Quarter 2022 Results

Call scheduled for today, May 12, at 4:30 pm ET TUCSON, Ariz. , May 12, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business…

Keep Reading

HTG Molecular Diagnostics to Announce Q1 2022 Financial Results and Host Conference Call on Thursday, May 12

TUCSON, Ariz. , May 05, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended…

Keep Reading

Publications

HTG Therapeutics White Paper HTP Proof of Concept
Download pdf 562KB


View All Publications

Page last updated March 22, 2022